Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
The present invention relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis, relapse or recurrence in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.
1. An in vitro method for designing a customized therapy for a subject having prostate cancer with bone metastasis comprising:
(i) contacting a prostate tumor sample from the subject with an antibody to quantify c-MAF gene expression level or amplification, and
(ii) comparing the expression level or amplification obtained in (i) with the expression level or amplification of the c-MAF gene in a control sample,
wherein the antibody comprises a heavy chain CDR1 of SEQ ID NO: 21, a heavy chain CDR2 of SEQ ID NO: 22, a heavy chain CDR3 of SEQ ID NO: 23, a light chain CDR1 of SEQ ID NO: 18, a light chain CDR2 of SEQ ID NO: 19, and a light chain CDR3 of SEQ ID NO: 20,
wherein if the expression level or amplification of the c-MAF gene in the tumor sample is increased with respect to the expression level or amplification of the c-MAF gene in the control sample, then said subject is susceptible to receive a therapy intended to prevent, inhibit and/or treat metastasis, relapse or recurrence of the cancer or a therapy intended to prevent or inhibit bone degradation.
2. The method according to claim 1 , wherein the bone metastasis is osteolytic metastasis.
3. The method according to claim 1 , wherein the therapy intended to prevent, inhibit and/or treat metastasis, relapse or recurrence of the cancer is selected from the group consisting of: a c-MAF inhibitory agent; a systemic treatment; radiotherapy; surgery; an mTor inhibitor; a Src kinase inhibitor; a CCR5 antagonist; a COX-2 inhibitor; and Alpharadin; and/or
wherein the therapy intended to prevent or inhibit bone degradation is selected from the group consisting of: a bisphosphonate, a RANKL inhibitor, a PTH or PTHLH inhibitor, a PRG analog, strontium ranelate, a DKK-1 inhibitor, a dual MET and VEGFR2 inhibitor, an estrogen receptor modulator, calcitonin, Radium-223, and a cathepsin K inhibitor.
4. The method according to claim 3 , wherein the bisphosphonate is clodronate or zoledronic acid.
5. The method according to claim 4 , wherein the bisphosphonate is clodronate.
6. The method according to claim 4 , wherein the bisphosphonate is zoledronic acid.
7. The method according to claim 3 , wherein the dual MET and VEGFR2 inhibitor is Cabozantinib.
8. The method according to claim 3 , wherein the RANKL inhibitor is selected from the group consisting of: a RANKL specific antibody, a RANKL-specific nanobody, and osteoprotegerin.
9. The method according to claim 8 , wherein the RANKL specific antibody is denosumab or the RANKL specific nanobody is ALX-0141.
10. The method according to claim 1 , wherein the amplification of the c-MAF gene is determined by means of determining the amplification of the locus 16q22-q24.
11. The method according to claim 1 , wherein the amplification of the c-MAF gene is determined by means of using a c-MAF gene-specific probe.
12. The method according to claim 1 , wherein the amplification of the c-MAF gene is determined by means of in situ hybridization or PCR.
13. The method according to claim 11 , wherein the c-MAF gene-specific probe is a Vysis LSI/IGH MAF Dual Color Dual Fusion Probe.
14. The method of claim 1 , wherein the increase of c-MAF expression is at least about 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 2 times, 3 times, 4 times, 5 times, 10 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, 100 times or greater than the control sample.
15. The method of claim 1 , wherein the expression level is measured using Western blot, ELISA, immunohistochemistry or a protein array.
16. A method for treating, inhibiting, reducing the risk of and/or preventing bone metastasis, relapse or recurrence from prostate cancer in a subject suffering prostate cancer, comprising:
(i) contacting a prostate tumor sample from the subject with an antibody to quantify c-MAF expression level,
(ii) comparing the expression level obtained in (i) with the expression level of the c-MAF in a control sample, wherein if the expression level of the c-MAF in the tumor sample is increased with respect to the expression level of the c-MAF in the control sample, then the subject is susceptible to receive zoledronic acid, and
(iii) administering zoledronic acid to a susceptible subject,
wherein the antibody comprises a heavy chain CDR1 of SEQ ID NO: 21, a heavy chain CDR2 of SEQ ID NO: 22, a heavy chain CDR3 of SEQ ID NO: 23, a light chain CDR1 of SEQ ID NO: 18, a light chain CDR2 of SEQ ID NO: 19, and a light chain CDR3 of SEQ ID NO: 20.
17. The method of claim 16 , wherein the increase of c-MAF expression is at least about 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 2 times, 3 times, 4 times, 5 times, 10 times, 20 times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times, 100 times or greater than the control sample.
18. The method of claim 16 , wherein the expression level is measured using Western blot, ELISA, immunohistochemistry or a protein array.
19. The method according to claim 16 , wherein the metastasis is osteolytic metastasis.
20. A method for treating, inhibiting, reducing the risk of and/or preventing bone metastasis, relapse or recurrence from prostate cancer in a subject suffering prostate cancer, comprising:
(i) contacting a prostate tumor sample from the subject with an antibody to quantify c-MAF expression level,
(ii) comparing the expression level obtained in (i) with the expression level of the c-MAF in a control sample, wherein if the expression level of the c-MAF in the tumor sample is increased with respect to the expression level of the c-MAF in the control sample, then the subject is susceptible to receive zoledronic acid or clodronate, and
(iii) administering zoledronic acid or clodronate to a susceptible subject,
wherein the antibody comprises a heavy chain CDR1 of SEQ ID NO: 21, a heavy chain CDR2 of SEQ ID NO: 22, a heavy chain CDR3 of SEQ ID NO: 23, a light chain CDR1 of SEQ ID NO: 18, a light chain CDR2 of SEQ ID NO: 19, and a light chain CDR3 of SEQ ID NO: 20.
21. The method according to claim 3 , wherein the estrogen receptor modulator is selected from the group consisting of: progestogen, estradiol, droloxifene, raloxifene, lasofoxifene, TSE-424, tamoxifen, idoxifene, LY353381, LY117081, toremifene, fulvestrant, 4-[7-(2,2-dimethyl-1-oxopropoxy-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl-2,2-dimethylpropanoate 4,4′ dihydroxybenzophenone-2,4-dinitrophenyl-hydrazone and SH646.
22. The method according to claim 21 , wherein the estrogen receptor modulator is fulvestrant.
23. The method according to claim 3 , wherein the systemic treatment is selected from the group consisting of: chemotherapy, hormone therapy, and immunotherapy.